PIL seeks sale of Covid vaccines
by SII, Bharat Biotech at Rs 150
A public interest litigation (PIL) has been filed in the Bombay
High Court challenging the different rates for COVID-19 vaccines
for the Centre and state governments and requesting direction to
the Serum Institute of India (SSI) and Bharat Biotech to sell their
vaccines at a uniform rate of Rs 150 per dose.
The PIL, filed on April 24 by advocate Fayzan Khan and three law
students, said the vaccine is presumed to be an essential
commodity and hence its management and distribution cannot be
left in the hands of private companies.
"These pharma giants are milking the fear psychosis of the
increased death rates due to COVID-19," it said.
Under the third phase of the national vaccination drive
commencing next month, the vaccine manufacturers would
supply 50 per cent of their monthly Central Drugs Laboratory
(CDL) released doses to the central government and would be
free to supply the remaining 50 per cent doses to state
governments and in the open market, the government had said.